Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Avidity Biosciences Inc (RNA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Avidity Bio's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
26.33 -0.12    -0.45%
06/05 - Closed. Currency in USD ( Disclaimer )
After Hours
26.58
+0.25
+0.95%
19:59:09 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 553,723
  • Bid/Ask: 25.87 / 26.69
  • Day's Range: 25.74 - 26.85
Avidity Bio 26.33 -0.12 -0.45%

Avidity Biosciences Inc Company Profile

 
Get an in-depth profile of Avidity Biosciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

253

Equity Type

ORD

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company’s lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Contact Information

Address 10578 Science Center Drive Suite 125
San Diego, 92121
United States
Phone 858 401 7900
Fax -

Top Executives

Name Age Since Title
Christopher J. Kirk 50 - Member of Scientific Advisory Board
Anna M. Wu - - Member of Scientific Advisory Board
Jean Jinsun Kim 48 2021 Independent Director
Richard A. Heyman 65 - Member of Scientific Advisory Board
Sarah Boyce 50 2019 President, CEO & Director
Eran Nadav 53 - Observer
Ryan B. Corcoran - - Member of Scientific Advisory Board
Tamar Thompson 48 2021 Independent Director
Frank P. McCormick 74 2012 Scientific Founder & Member of Scientific Advisory Board
Troy Edward Wilson 55 2012 Co-Founder & Independent Chairman
Arthur A. Levin 70 2019 Distinguished Scientist, Strategic Leader & Director
Mark E. Davis - 2012 Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
Noreen Roth Henig 59 2019 Independent Director
Carsten Boess 58 2020 Independent Director
Edward M. Kaye 75 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RNA Comments

Write your thoughts about Avidity Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mohamed Gad
Mohamed Gad Feb 16, 2021 1:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
should I buy now
Roy mu
Roy mu Feb 16, 2021 1:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It is at bottom, so it doesn't hurt if you buy here. But you have to be patient.  The 288 338 channel is way above 144 and 169, which means it gonna take some time for the stock to attract attention from the market. Maybe it is better to use your money otherwhere at this time, only becasue the stock hasn't built up momentum yet.  But once some news out, it will trigger the up trend.
Mohamed Gad
Mohamed Gad Feb 16, 2021 1:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
roy mu . do u recommend any other stock
Samuel Hong
Samuel Hong Jun 12, 2020 6:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
300 shares @ $28.45.
En Game
En Game Jun 12, 2020 6:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
just bought at the close at 22.39  lets see it
Samuel Hong
Samuel Hong Jun 11, 2020 5:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Watching this one.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email